1. Flow cytometric analysis of anti-ERBB2 CAR expression. 293 cells were lentivirally transduced with anti-ERBB2 CAR. Flow cytometric analysis was performed with a negative control protein and HER2/ERBB2 Protein, Human, Recombinant (His), AF488-Labeled (Cat#TMPY-06993), respectively. Non-transduced 293 cells were used as a control (left).
2. Binding activity of PE-conjugated EGFR protein to PBMC cells. PBMC cells were stained with anti-CD3 antibody and HER2/ERBB2 Protein, Human, Recombinant (His), AF488-Labeled (Cat#TMPY-06993) and detected by flow cytometry. PBMC cells stained with anti-CD3 antibody were used as a control (left).

HER2/ERBB2 Protein, Human, Recombinant (His), AF488-Labeled is expressed in HEK293 Cells. The accession number is P04626.

Human

HEK293 Cells

VSCN2,TKR1,p185(erbB2),NGL,NEU,MLN-19,MLN19,MLN 19,HER-2/neu,HER-2,HER2,c-ERB-2,c-ERB2,CD340

A DNA sequence encoding the extracellular domain (Met1-Thr652) of human ERBB2 (NP_004439.2) was expressed with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 488 (Excitation Max.= 495 nm, Emission Max.= 519 nm).

≥ 90% as determined by SDS-PAGE.

Please refer to the lot-specific COA.

Twelve months from date of receipt at -20℃ to -70℃ in lyophilized form and 3 months at -70℃ under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles.

Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy